Actuate Therapeutics Inc

NASDAQ:ACTU

Biotechnology

Healthcare
$2.09 +2.96%

+$0.06 today

Market cap
$50.01M
Beta
0.53
P/E (TTM)
-2.3
EPS (TTM)
-$0.92
52W Low $1.58High $9.22

Volume 0.03M

Average 0.16M

Fair Value & DCF

Compare our fair value with your own assumptions

Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.

Actuate Therapeutics Inc

NASDAQ:ACTU

Intrinsic Alpha fair value

Locked

Current Price

$2.09

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.

Build your own valuation

Test an independent scenario and compare it with Intrinsic Alpha's estimate.

Sign in to use the DCF calculator

Free accounts get 5 valuations per week. Upgrade for more.

Sign in / Sign up

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/AN/A
N/A3 analysts
Net IncomeN/AN/AN/A
N/A3 analysts
EBITN/AN/AN/A
N/A3 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Estimates & History

Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.

Further estimates hidden. Sign in to unlock

Competitor Valuations

Peer stocks ranked by intrinsic value status

CompanyMarket CapPriceValuationP/E1Y Return

Nkarta, Inc.

NASDAQ:NKTX

$195.68M$2.74Not rated-2.0-37.43%

Alector, Inc.

NASDAQ:ALEC

$174.86M$1.58Not rated-1.4+88.52%

Molecular Partners AG

NASDAQ:MOLN

$148.22M$3.95Not rated-2.0-38.90%

Spero Therapeutics, Inc.

NASDAQ:SPRO

$129.13M$2.23Undervalued8.2-63.28%

PepGen Inc.

NASDAQ:PEPG

$120.70M$1.75Not rated-1.6-28.93%

Vor Biopharma Inc.

NASDAQ:VOR

$103.52M$15.10Not rated-0.0+136.83%

Elicio Therapeutics, Inc.

NASDAQ:ELTX

$71.95M$3.77Not rated-1.7-66.67%

Seres Therapeutics, Inc.

NASDAQ:MCRB

$62.56M$6.46Overvalued-1.3-81.56%